Walvax Biotechnology COVID booster stronger against Omicron than Sinovac shot, shows trial data
Beijing: A COVID-19 vaccine candidate from China's Walvax Biotechnology using mRNA technology triggered a stronger antibody response against the Omicron variant of the coronavirus as a booster dose than Sinovac's shot, clinical trial data showed.The result for Walvax's ARCoV candidate, which is yet to be peer reviewed, comes as competition for the COVID booster market intensifies in China,...
Beijing: A COVID-19 vaccine candidate from China's Walvax Biotechnology using mRNA technology triggered a stronger antibody response against the Omicron variant of the coronavirus as a booster dose than Sinovac's shot, clinical trial data showed.
Read also: Sinovac, Sinopharm Omicron-specific vaccine candidates approved for clinical trial in Hong Kong
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd